MDS Nordion, a provider of medical isotopes and radiopharmaceuticals, has formed an agreement with the Karpov Institute of Physical Chemistry in Moscow to study the feasibility of the Institute to provide MDS with a supply of molybdenum-99 (Mo-99) for the nuclear medicine market.
The Ottawa, Ontario-based MDS and the Karpov Institute have agreed to combine their respective resources to explore the development of a commercialization plan to address a portion of the need for a long-term supply of Mo-99.
The Karpov Institute of Physical Chemistry has been involved in basic and applied research in the area of physical chemistry for more than 90 years. Production of medical isotopes and radiopharmaceuticals are developed using the Institute's WWR-c research reactor.
Karpov said it is the supplier of 90 percent of the Mo-99 and Tc-99m generators to the Russian market.